ERBB2 and neoplasm: The repeated activation of NK cells upon treatment with the irrelevant fusion protein αGC/sCD1d-anti-HER2 indicated that sustained systemic activation of iNKT cells had occurred, although to a weaker extent than with the tumor-targeted treatment.